Pages that link to "Q34516784"
Jump to navigation
Jump to search
The following pages link to Risperidone-related weight gain: genetic and nongenetic predictors (Q34516784):
Displaying 50 items.
- Management of antipsychotic-related weight gain (Q24610124) (← links)
- CYP2D6 polymorphisms and their influence on risperidone treatment (Q28079227) (← links)
- Genetics of weight gain associated with antipsychotic medications (Q33408581) (← links)
- Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. (Q33660225) (← links)
- Pharmacogenetics of antipsychotics (Q33836837) (← links)
- Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles (Q34006864) (← links)
- Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. (Q34273354) (← links)
- Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study (Q34329113) (← links)
- Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene (Q34413008) (← links)
- Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction (Q34676533) (← links)
- 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies (Q34719766) (← links)
- Risperidone induced weight gain leading to benign intracranial hypertension (Q35145284) (← links)
- Pharmacogenetics of antipsychotic-induced side effects (Q35237129) (← links)
- Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain (Q36441507) (← links)
- Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents (Q36530878) (← links)
- Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort (Q36556433) (← links)
- Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population (Q36747019) (← links)
- Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research (Q36840610) (← links)
- No Association between Serotonin Receptor 2C-759C/T Polymorphism and Weight Change or Treatment Response to Mirtazapine in Korean Depressive Patients. (Q36941595) (← links)
- HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis (Q36950578) (← links)
- Pharmacogenetics in psychiatry: are we ready for widespread clinical use? (Q37076472) (← links)
- Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications (Q37220366) (← links)
- Drug-induced hyperphagia: what can we learn from psychiatric medications? (Q37254782) (← links)
- Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. (Q37422493) (← links)
- 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment (Q37719385) (← links)
- Risperidone-Induced Adverse Drug Reactions and Role of DRD2 (-141 C Ins/Del) and 5HTR2C (-759 C>T) Genetic Polymorphisms in Patients with Schizophrenia. (Q37725986) (← links)
- Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses (Q37793826) (← links)
- Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. (Q37917782) (← links)
- Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. (Q37926893) (← links)
- Pharmacogenetics of response to antipsychotics in patients with schizophrenia (Q37952823) (← links)
- Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia (Q37960512) (← links)
- Atypical antipsychotic-induced weight gain: insights into mechanisms of action (Q37963571) (← links)
- Pharmacogenetics of clinical response to risperidone. (Q38074712) (← links)
- Pharmacogenetics of risperidone: a systematic review of the clinical effects of CYP2D6 polymorphisms (Q38086817) (← links)
- Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy (Q38154911) (← links)
- Individualizing clozapine and risperidone treatment for schizophrenia patients (Q38170458) (← links)
- Pharmacogenetics of second-generation antipsychotics (Q38217628) (← links)
- HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis (Q38242739) (← links)
- Weight gain with add-on second-generation antipsychotics in bipolar disorder: a naturalistic study (Q38838191) (← links)
- Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis (Q38842714) (← links)
- Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients (Q40255006) (← links)
- Association Study of Brain-Derived Neurotrophic Factor Gene Polymorphisms and Body Weight Change in Schizophrenic Patients Under Long-Term Atypical Antipsychotic Treatment (Q46117105) (← links)
- The role of genetic variation across IL-1β, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain (Q46716221) (← links)
- Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children (Q47161187) (← links)
- A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population (Q47348196) (← links)
- The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. (Q48107672) (← links)
- Association Between 5-HTR2C -759C/T (rs3813929) and -697G/C (rs518147) Gene Polymorphisms and Risperidone-Induced Insulin Resistance Syndrome in an Indian Population (Q48304926) (← links)
- A preliminary study of association of genetic variants with early response to olanzapine in schizophrenia. (Q55342505) (← links)
- Metabolic syndrome in patients with schizophrenia independently from atypical antipsychotics intake (Q82874214) (← links)
- Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism (Q90294280) (← links)